Session » Systemic Sclerosis, Fibrosing Syndromes and Raynaud's – Clinical Aspects and Therapeutics Poster I

Date: Sunday, November 5, 2017

Time: 9:00AM-11:00AM

Meeting: 2017 ACR/ARHP Annual Meeting

9:00AM-11:00AM: Abstract Number: 745

An International Qualitative Research Study Exploring the Patient Experience of Raynaud’s Phenomenon in Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 724

Antibodies Against the Chemokine Receptors CXCR3 and CXCR4 Predict Progressive Lung Fibrosis in Systemic Sclerosis (SSc)

9:00AM-11:00AM: Abstract Number: 747

Autoantibodies to Rpp25 (Th/To) Are Specific Markers for Systemic Sclerosis and Are Associated with Limited Cutaneous Disease and Young Age at Disease Onset

9:00AM-11:00AM: Abstract Number: 741

Cardiac MRI in Systemic Sclerosis As Prognostic Tool of Cardiac Mortality in Symptomatic Patients

9:00AM-11:00AM: Abstract Number: 735

Cardiopulmonary Exercise Testing to “Detect” Pulmonary Arterial Hypertension in Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 729

Clinically Relevant Serum Proteins in Patients with Early Diffuse Cutaneous Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 746

Comparison of Disease Characteristics in Patients with Juvenile-Onset and Adult-Onset Progressive Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 734

Correlation of the American College of Rheumatology Provisional Composite Response Index in Systemic Sclerosis with Serum Biomarkers of Fibrogenesis in an Observational Cohort

9:00AM-11:00AM: Abstract Number: 750

Diltiazem Gel As a New Local Treatment for Scleroderma Digital Ulcers

9:00AM-11:00AM: Abstract Number: 737

Dynamic Prediction of Pulmonary Hypertension Development in Systemic Sclerosis Patients Using Landmark Analysis – Comparison of Two Models

9:00AM-11:00AM: Abstract Number: 751

Effect of Probiotics on the Gastrointestinal Symptoms and Immune Parameters in Patients with Systemic Sclerosis: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial

9:00AM-11:00AM: Abstract Number: 733

Ethnic Variation in Systemic Sclerosis Morbidity and Mortality

9:00AM-11:00AM: Abstract Number: 739

How Effective Is the Home Exercise Program for Hands in Patients with Systemic Sclerosis: Preliminary Results from a Randomized Controlled, Single-Blind, Clinical Trial

9:00AM-11:00AM: Abstract Number: 743

Impact of Detect on Right Heart Catheterization Referral and Results; Data from a Prospective, Unselected, Systemic Sclerosis Cohort

9:00AM-11:00AM: Abstract Number: 736

N-Terminal Pro-Brain Natriuretic Peptide Is Disproportionately Elevated in Scleroderma Associated Pulmonary Arterial Hypertension Compared to Idiopathic Pulmonary Arterial Hypertension

9:00AM-11:00AM: Abstract Number: 726

Performance of the American College of Rheumatology Provisional Composite Response Index in Systemic Sclerosis (CRISS) in the Scleroderma Lung Study-I

9:00AM-11:00AM: Abstract Number: 744

Prediction of All-Cause Mortality and Pulmonary Arterial Hypertension (PAH) Progression in Systemic Sclerosis (SSc), an Echocardiography Study

9:00AM-11:00AM: Abstract Number: 740

Prediction of Fibrosis Progression in Systemic Sclerosis By Collagen Biomarkers

9:00AM-11:00AM: Abstract Number: 731

Prediction of Progression of Interstitial Lung Disease in Patients with Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 732

Progression of Skin Fibrosis Is Associated with Decline in Lung Function in Patients with Diffuse Cutaneous Systemic Sclerosis: A European Scleroderma Trials and Research (EUSTAR) Analysis

9:00AM-11:00AM: Abstract Number: 738

Prospective Validation of the Systemic Sclerosis Skin Symptoms Patient-Reported Outcome (SSPRO) in a Phase 2 Trial of Anabasum (JBT-101) in Diffuse Cutaneous Systemic Sclerosis (dcSSc)

9:00AM-11:00AM: Abstract Number: 742

Quantitative CT Evalutation in Diffuse Interstitial Lung Involvement in Systemic Sclerosis: Usefulness of Lung Texture Analysis to Predict the Functional Change over Time

9:00AM-11:00AM: Abstract Number: 752

Role of the Six-Minute Walk Test in Systemic Sclerosis: Five Years Evolution

9:00AM-11:00AM: Abstract Number: 725

Safety and Efficacy of Anabasum (JBT-101) in Diffuse Cutaneous Systemic Sclerosis (dcSSc) Subjects Treated in an Open-Label Extension of Trial JBT101-SSc-001

9:00AM-11:00AM: Abstract Number: 748

Scleromyxedema Phenotype Pre- and Post-Treatment with Intravenous Immunoglobulin

9:00AM-11:00AM: Abstract Number: 727

Survival and Clinical-Capillaroscopic Characteristics of French Canadian Systemic Sclerosis Patients: Analysis Based on Systemic Sclerosis Autoantibodies and the Novel Anti-BICD2 Autoantibody

9:00AM-11:00AM: Abstract Number: 728

Symptoms of Autonomic Dysfunction in Systemic Sclerosis Assessed By the Compass-31 Questionnaire

9:00AM-11:00AM: Abstract Number: 730

The Association of Pulmonary Hypertension with Isolated Nucleolar Serum Autoantibodies in Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 749

Treatment with Cyclophosphamide for Systemic Sclerosis-Interstitial Lung Disease Does Not Lead to a Sustained Improvement in Lung Function in Two Independent Cohorts

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].